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Abstract
Acute kidney injury (AKI) is a very common complication after allogeneic bone marrow transplantation (BMT) and is
associated with a poor prognosis. Generally, the kidneys are assumed to not be no direct targets of graft-versus-host
disease (GvHD), and renal impairment is often attributed to several other factors occurring in the early phase after BMT.
Our study aimed to prove the existence of renal GvHD in a fully major histocompatibility complex (MHC)-mismatched
model of BALB/c mice conditioned and transplanted according to 2 different intensity protocols. Syngeneically transplanted
and untreated animals served as controls. Four weeks after transplantation, allogeneic animals developed acute GvHD that
was more pronounced in the high-intensity protocol (HIP) group than in the low-intensity protocol (LIP) group. Urea and
creatinine as classic serum markers of renal function could not verify renal impairment 4 weeks after BMT. Creatinine levels
were even reduced as a result of catabolic metabolism and loss of muscle mass due to acute GvHD. Proteinuria, albu-
minuria, and urinary N-acetyl-beta-D-glucosaminidase (NAG) levels were measured as additional renal markers before and
after transplantation. Albuminuria and NAG were only significantly increased after allogeneic transplantation, correlating
with disease severity between HIP and LIP animals. Histological investigations of the kidneys showed renal infiltration of T
cells and macrophages with endarteriitis, interstitial nephritis, tubulitis, and glomerulitis. T cells consisted of CD4þ, CD8þ,
and FoxP3þ cells. Renal expression analysis of allogeneic animals showed increases in indoleamine-2,3 dioxygenase (IDO),
different cytokines (tumor necrosis factor a, interferon-g, interleukin 1 a [IL-1a], IL-2, IL-6, and IL-10), and adhesion
molecules (intercellular adhesion molecule 1 and vascular cell adhesion molecule 1), resembling findings from other tissues
in acute GvHD. In summary, our study supports the entity of renal GvHD with histological features suggestive of cell-
mediated renal injury. Albuminuria and urinary NAG levels may serve as early markers of renal impairment.
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Introduction
Since its clinical introduction in the early 1960s, allogeneic
bone marrow transplantation (BMT) has been increasingly
used for the treatment of malignant and nonmalignant dis-
eases. Often, BMT is the only curative treatment option
available.1 Despite the development of novel strategies and
the improved treatment of side effects, graft-versus-host dis-
ease (GvHD) remains a life-threatening complication, limit-
ing an even broader use of BMT. In general, the skin, liver,
and gastrointestinal tract are the main targets in acute
GvHD.2 Although up to 70% of patients develop acute kid-
ney injury (AKI) after allogeneic BMT,3 the kidneys are not
assumed to be a direct target of T cells in acute GvHD.
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Instead, several other factors are responsible for renal
impairment in the early phase after BMT, such as tumor
lysis, sepsis, nephrotoxic medications, hepatic veno-
occlusive disease, or thrombotic microangiopathy.3-6 How-
ever, GvHD as a severe inflammatory disease may also
indirectly cause nephropathy.7 The exact etiology of renal
dysfunction after BMT often remains unclear, because no
renal biopsy is taken in most cases. However, AKI is a risk
factor for developing chronic kidney disease (CKD) and is
associated with increased morbidity and mortality.8,9
Chronic GvHD of the kidneys has been described in several
studies,10-12 but reports of GvHD resulting in nephrotic syn-
drome are rare.13 In contrast, only some studies have indi-
cated renal involvement in acute GvHD.14,15 A recent study
specifically addressing this topic has described cell infiltra-
tion suggestive of acute GvHD of the kidneys in a rat model
of allogeneic BMT.16
In our present study, we used a fully mismatched mouse
model of GvHD to further investigate whether kidneys are a
target of acute GvHD and to characterize pathophysiological
processes involved.
Materials and Methods
Bone Marrow Transplantation
Animal experiments were approved by the institutional animal
committee of the University of Regensburg and conducted in
accordance with German animal protection laws. The trans-
plantation procedurewas conducted as recently described else-
where.17,18 In short, female C57BL/6 N (H-2b) and BALB/c
(H-2d) mice (Charles River, Sulzbach, Germany) were trans-
planted at an age of 11 to 12wks. First, BALB/c recipient mice
were conditioned with lethal total body irradiation using a
linear accelerator (150 cGy/min). A mixture of bone marrow
cells and splenocytes from either syngeneic (BALB/c, synTx)
or allogeneic (C57BL/6, alloTx) donors was injected through
the tail vein. The effect of different transplantation conditions
on alterations of the kidneys was tested by diversifying the
irradiation dose as well as the count of transplanted bone mar-
row cells and splenocytes according to 2 different intensity
protocols (Table 1). Untreated animals of the same age were
used as controls to detect possible effects of irradiation and
transplantation procedures (n¼ 5, ctrl).
Clinical GVHD Score, Serum, and Urine Samples
After transplantation, clinical GVHD scores were assessed
weekly by a well-established standard scoring system incor-
porating weight loss, posture (hunching), mobility, fur tex-
ture, and skin integrity.19 Each parameter was graded
between 0 and 2 followed by calculation of the cumulative
score for each mouse. Blood samples were obtained imme-
diately after euthanasia in week þ4. Urine samples were
taken the week before transplantation and in the third week
after transplantation to measure protein (Pierce protein
method with bicinchoninic acid solution (B-9643, Sigma-
Aldrich, Munich, Germany) and copper(II) sulfate solution
(C-2284, Sigma-Aldrich) and albumin (enzyme-linked
immunosorbent assay (ELISA) #ab108792, Abcam, Cam-
bridge, MA, USA) content as well as creatinine (enzymatic
kinetic colorimetric method (creatinine peroxidase-antiperox-
idase (PAP) test) #LT-CR-0101, LaborþTechnik, Berlin,
Germany) and N-acetyl-beta-D-glucosaminidase (NAG;
ELISA #MBS703771, My BioSource, San Diego, CA, USA)
levels. The albumin to creatinine ratio was calculated. Four
weeks after transplantation, animals were euthanized, blood
samples were taken, and creatinine as well as blood urea
nitrogen (enzymatic ultraviolet method (urea UV test) #LT-
UR-0010, LaborþTechnik, Berlin, Germany) levels were
measured to test renal function. After that, the kidneys were
prepared for further investigation.
Histology and Immunohistochemistry
For histological analysis, the kidneys were fixed in 20%
buffered formalin and embedded in paraffin. Tissue samples
were stained with hematoxylin/eosin (HE; Merck, Darm-
stadt, Germany) and periodic-acid-Schiff (PAS; Roth, Karls-
ruhe, Germany) for light microscopy. For detection of
infiltrating T cells and macrophages, tissues were incubated
with CD3 (anti-CD3 #ab16669, Abcam), CD4 (anti-CD4-
Aff–Purified #AP20210PU-N, Acris, Herford, Germany),
CD8 (anti-CD8 #bs-0648 R, Bioss Antibodies Inc., Woburn,
MA, USA), forkhead box P3 (anti-FoxP3 #ab54501,
Abcam), and MAC2 (anti-MAC2 #CL8942AP, Cedarlane,
Burlington, Ontario, Canada) antibodies. To verify that
CD4þ, CD8þ, and FoxP3þ cells were T cells, we per-
formed a double staining with CD3 (anti-CD3 #ab5690 and
anti-FoxP3 #ab54502, Abcam; anti-CD4 #14-9766,
eBioscience, San Diego, CA, USA; anti-CD8 #bs-0648 R,
Bioss Antibodies Inc., Woburn, MA, USA). Additionally,
apoptosis was detected by means of a terminal deoxynucleo-
tidyl transferase deoxyuridine triphosphate nucleotide
(dUTP) nick end labeling (TUNEL) assay (TUNEL
#G7130, Promega, Mannheim, Germany). In each kidney,
the number of infiltrating CD3þ T cells, CD4þ T cells,
CD8þ T cells, FoxP3þ T cells, and MAC2þ macrophages
as well as apoptotic cells was counted in 20 randomly
selected interstitial fields of view at 40 magnification.
Messenger RNA Expression in Kidneys
The expression of indoleamine-2,3 dioxygenase (IDO),
different cytokines, intercellular adhesion molecule 1
(ICAM-1), and vascular cell adhesion molecule 1
(VCAM-1; Table 2) was quantified by real-time polymerase
chain reaction (RT-PCR). In brief, kidneys were collected,
and total RNA was extracted (RNeasy kit, Quiagen, Hilden,
Germany) according to the manufacturer’s instructions. A
deoxyribonuclease digestion step was included. The absor-
bance ratios A260/280 and A260/230 were calculated as
measures of RNA purity; for all samples, only ratios >2 were
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accepted. For first-strand complementary DNA (cDNA)
synthesis, 1 mg of total RNA was reverse transcribed with
1UMoloneyMurine Leukemia Virus reverse transcriptase, 1
mg random primer, 1 mM deoxynucleotide triphosphate mix-
ture, 1 mL recombinant RNasin ribonuclease inhibitor, and
transcription buffer with 5 mM MgCl2 in a final volume of
10 mL (all from Promega, Mannheim, Germany). The reac-
tion mixture was incubated at 37C for 60 min, followed by
heat inactivation of the enzyme at 95C for 5 min. In parallel,
1 mg of total RNA was processed without reverse transcrip-
tion to control for contamination with genomic DNA. After
cooling on ice for 5 min, the cDNA was stored at 20C
until further use. Real-time polymerase chain reaction was
detected using the ABIPrism 7900 TaqMan, and data were
analyzed with SDS Version 2.2.2 software (Applied Biosys-
tems, Foster City, CA, USA). Beta-actin served as house-
keeping gene for normalization of input amounts. For the
relative quantification of target genes, a standard curve
method with a cDNA pool from each single target sample
was used. Measurements were carried out in triplicate, and
their means were calculated for each animal.
Data Analysis
All data are shown as mean + standard error of the mean
(SEM). Differences among the treatment groups were
evaluated either by analysis of variance (ANOVA) (Holm-
Sidak as post hoc test) or Student’s t test as appropriate with
a software program (SigmaPlot, Systat Software Inc., San
Jose, CA, USA). The following groups were compared by
ANOVA: ctrl versus alloTx(HIP) versus synTx(HIP), ctrl ver-
sus alloTx(LIP) versus synTx(LIP), ctrl versus alloTx(HIP)
versus alloTx(LIP), ctrl versus synTx(HIP) versus
synTx(LIP). A P value of <0.05 was considered significant.
Results
Body Weight and GvHD Score as Markers of Acute
Systemic GvHD
The average body weight before transplantation was about
20 g in each group. By week þ4 after allogeneic BMT, the
weight of the mice had decreased by 24.6% in the HIP group
and by 9.9% in the LIP group. Syngeneic animals in both
protocol groups showed only a transient loss of body weight
in week þ1 (synTx(LIP): 7.9%, synTx(HIP):11.1%) but
had fully recovered by week þ4 (synTx(LIP): þ5.3%,
synTx(HIP): þ6.9%). In contrast, untreated controls showed
a continuous increase in body weight by 16.2% during the
animal experiment. These changes were significant in allo-
geneic animals in comparison with all other groups in week
þ4 before euthanasia and the subsequent investigations of
the kidneys (P < 0.001 for alloTx(HIP) vs. ctrl, synTx(LIP)
Table 2. Primer Sequences Used for Gene Expression Analysis.
Gene Forward Primer Reverse Primer Company
IDO CCGGTCACGAATGTGGAACT AGCTGCCCGTTCTCAATCAG Eurofins
eNOS Mm00435217_m1 Applied Biosystems
iNOS Mm00440502_m1 Applied Biosystems
TNF-a AGGCACTCCCCCAAAAGATG TTTGCTACGACGTGGGCTAC Eurofins
IFN-g CTTCAGCAACAGCAAGGCG AGCGACTCCTTTTCCGCTTC Eurofins
IL-1a Mm00439620_m1 Applied Biosystems
IL-1b Mm00434228_m1 Applied Biosystems
IL-2 TTTTACTTGCCCAAGCAGGC GAAAGTCCACCACAGTTGCTG Eurofins
IL-4 CAAACGTCCTCACAGCAACG GGCATCGAAAAGCCCGAAAG Eurofins
IL-6 Mm00446190_m1 Applied Biosystems
IL-10 AAGGGTTACTTGGGTTGCCA GAAATCGATGACAGCGCCTC Eurofins
IL-11 Mm00434162_m1 Applied Biosystems
ICAM-1 CACGCTACCTCTGCTCCT AGGCTTCTCTGGGATGGATG Eurofins
VCAM-1 TCTTGGGAGCCTCAA CGTAGTGCTGCAAGTGAG Eurofins
Beta-actin Mm04394036_g1 Applied Biosystems
Abbreviations: eNOS, endothelial nitric oxide synthase; iNOS; inducible nitric oxide synthase; IDO, indoleamine-2,3 dioxygenase; IFN-g, interferon g; IL,
interleukin; ICAM-1, intercellular adhesion molecule 1; TNF-a, tumor necrosis factor a; VCAM-1, vascular cell adhesion molecule 1.
Table 1. Conditions of the 2 Transplantation Protocols and Numbers of Transplanted Animals.
Protocol Irradiation Dose [Gy] BMC [106] SC [106] alloTx [n] synTx [n]
Low-intensity protocol Tx 8 2 1 8/7 5/5
High-intensity protocol Tx 9 2.5 2 8/5 5/4
Abbreviations: alloTx, number of allogeneically transplanted and surviving animals after 4 weeks; BMC, transplanted bone marrow cells; Gy, Gray; HIP, high-
intensity protocol; LIP, low-intensity protocol; SC, transplanted splenocytes; synTx, number of syngeneically transplanted and surviving animals after 4 weeks.
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and synTx(HIP); P < 0.001 for alloTx(LIP) vs. ctrl; P < 0.05
for alloTx(HIP) vs. alloTx(LIP) and for alloTx(LIP) vs.
synTx(LIP) and synTx(HIP)). According to their weight
changes, allogeneic animals also showed distinct clinical
signs of acute GvHD as indicated by the GvHD score. Four
weeks after the allogeneic transplantation, HIP animals
reached a GvHD score of 6.0+ 0.3, which was significantly
higher than that in the LIP group with 3.9+ 0.7 (P¼ 0.048).
In contrast, syngeneic animals had no signs of relevant
GvHD in weekþ4 with values of 1.4+ 0.1 in the LIP group
and 2.2 + 1.1 in the HIP group. These results were already
summarized in our recent publication.18
Parameters of Renal Function After BMT
Figure 1 depicts important markers of renal function in
serum and urine. Serum urea levels (Fig. 1A) in each group
did not show any significant differences (ctrl: 42.1 + 2.6
mg/dL; alloTx(LIP): 37.0 + 2.0 mg/dL; synTX(LIP): 36.9
+ 1.1 mg/dL; alloTx(HIP): 41.5+ 1.8 mg/dL; synTx(HIP):
38.5 + 3.9 mg/dL). Serum creatinine (Fig. 1B) was signif-
icantly lower in allogeneic animals than in control and syn-
geneic animals (ctrl: 18.1 + 0.6 mg/dL; alloTx(LIP): 10.4
+ 1.8 mg/dL; synTX(LIP): 18.8+ 2.4 mg/dL; alloTx(HIP):
9.7 + 1.1 mg/dL; synTx(HIP): 14.3 + 1.9 mg/dL). Urine
analysis in the week before (week 1) and 3 weeks after
transplantation (week þ3) showed a significant increase in
albuminuria objectified by the albumin/creatinine ratio (Fig.
1C) after allogeneic transplantation (alloTx(LIP) week 1:
11.6 + 1.6 mg/g, week þ3: 20.1 + 2.6 mg/g; alloTx(HIP)
week 1: 10.4+ 1.2 mg/g, week þ3: 31.1+ 6.2 mg/g). A
comparison of allogeneic animals showed significantly
higher albuminuria levels in the HIP group than in the LIP
group. In contrast, no significant changes could be observed
for control and syngeneic animals between the 2 time points
(ctrl week 1: 8.4 + 0.5 mg/g, week þ3: 7.3 + 1.8 mg/g;
synTx(LIP) week 1: 15.2 + 2.4 mg/g, week þ3: 12.5 +
0.9 mg/g; synTx(HIP) week 1: 9.4+ 0.5 mg/g, week þ3:
10.9+ 1.7 mg/g). In the LIP group, allogeneic animals had
significantly higher albuminuria levels than control and syn-
geneic animals, and the same results applied to the HIP
group. However, total urinary protein levels, also measured
as protein/creatinine ratio, showed no changes between week
1 and week þ3 (ctrl week 1: 33.8 + 3.3 g/g, week þ3:
36.0+ 4.8 g/g; alloTx(LIP) week 1: 59.1+ 6.1 g/g, week
þ3: 52.7 + 3.6 g/g; synTx(LIP) week 1: 59.2 + 4.4 g/g,
weekþ3: 45.5+ 2.7 g/g; alloTx(HIP) week1: 43.1+ 3.7
g/g, week þ3: 50.8+ 10.6 g/g; synTx(HIP) week 1: 35.1
+ 4.9 g/g, week þ3: 37.2+ 4.7 g/g). As a novel marker of
renal function, we also assessed urinary NAG levels (Fig.
1D). Similar to albuminuria, NAG was significantly
increased after allogeneic transplantation in both the LIP and
the HIP groups (alloTx(LIP) week1: 240.6+ 2.1 mUI/mL,
week þ3: 354.1 + 6.1 mUI/mL; alloTx(HIP) week 1:
330.7 + 4.1 mUI/mL, week þ3: 361.1 + 5.3 mUI/mL).
Apart from albuminuria levels, the difference between
allogeneic LIP and HIP animals was not statistically signif-
icant. All of the other animals did not show any significant
change in urinary NAG levels at the 2 time points (ctrl week
1: 229.8 + 2.5 mUI/mL, week þ3: 333.2 + 1.8 mUI/mL;
synTx(LIP) week1: 337.1+ 3.0 mUI/mL, weekþ3: 339.4
+ 2.4 mUI/mL; synTx(HIP) week 1: 331.03 + 2.1 mUI/
mL, week þ3: 341.2+ 3.3 mUI/mL). Allogeneic animals in
the LIP group showed significantly higher NAG levels than
control animals, whereas allogeneic animals in the HIP
group had significantly higher NAG levels than both control
and syngeneic animals.
Histological Alterations in Kidneys after BMT
Figure 2 shows representative histological alterations in kid-
neys after allogeneic (A to D) compared to syngeneic trans-
plantation (E and F). A pathological infiltration of
mononuclear cells into the renal interstitium was only found
in allogeneic animals. Immunohistological characterization
showed mainly CD3þ T cells (Fig. 3A to D) and MAC2þ
macrophages (Fig. 3E and F) that reached from the perivascu-
lar tissue into the renal interstitium, infiltrating tubules, and
glomeruli. Concomitantly with cellular infiltration, we
detected apoptosis of tubular and glomerular cells as illustrated
by TUNEL staining (Fig. 3G and H). Such changes were not
observed after syngeneic BMT (Figs. 2e and f and 3I and K) or
in untreated controls (not shown). Quantification of the infil-
trating cells (Fig. 4) showed significantly more CD3þ T -cells
in kidneys after allogeneic transplantation than in control and
syngeneic animals (ctrl: 1.2+ 0.1 cells/field; synTx(LIP): 1.2
+ 0.4 cells/field; alloTx(LIP): 10.1+ 1.2 cells/field; synTx(-
HIP): 1.4 + 0.2 cells/field; alloTx(HIP): 11.4 + 0.9 cells/
field). The same applied to MAC2þ macrophages that con-
tained more cells after allogeneic BMT (ctrl: 1.6+ 0.4 cells/
field; synTx(LIP): 2.7+ 0.1 cells/field; alloTx(LIP): 13.8+
1.2 cells/field; synTx(HIP): 2.1+ 0.3 cells/field; alloTx(HIP):
11.1+ 1.2 cells/field). Kidneys of all animals after allogeneic
transplantation (7 of 7 in the LIP group and 5 of 5 in the HIP
group) were affected by CD3þ and MAC2þ cell infiltrates.
Double staining revealed CD4þ, CD8þ, and FoxP3þ cells
costaining with CD3, which confirmed that they represent T
cells. Their quantification again showed significantly more
CD4þ T cells (ctrl: 1.0+ 0.3 cells/field; synTx(LIP): 1.6+
0.2 cells/field; alloTx(LIP): 4.1+ 0.6 cells/field; synTx(HIP):
2.2+ 0.5 cells/field; alloTx(HIP): 3.6+ 0.2 cells/field) and
FoxP3þ (ctrl: 0.6 + 0.1 cells/field; synTx(LIP): 1.1 + 0.1
cells/field; alloTx(LIP): 2.9+ 0.1 cells/field; synTx(HIP): 1.0
+ 0.2 cells/field; alloTx(HIP): 2.4 + 0.1 cells/field) in ani-
mals after allogeneic transplantation. Differences in CD8þ T
cells were not significant among the different groups (ctrl: 2.5
+ 0.2 cells/field; synTx(LIP): 1.6+ 0.2 cells/field; alloTx(-
LIP): 1.7+ 0.2 cells/field; synTx(HIP): 2.2+ 0.2 cells/field;
alloTx(HIP): 2.1 + 0.2 cells/field). A significant difference
between the 2 allogeneic animal groups was only found for
FoxP3þ T cells that were more often detected in LIP animals
with less severe disease than in the HIP group. Quantification
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of TUNELþ cells showed a significant increase in apoptotic
cells in allogeneic animals of both protocol groups (ctrl: 1.5+
0.7 cells/field; synTx(LIP): 5.5+ 1.5 cells/field; alloTx(LIP):
18.3 + 3.1 cells/field; synTx(HIP): 6.3 + 1.9 cells/field;
alloTx(HIP): 18.7.1 + 3.0 cells/field). Such TUNELþ cells
were found in 5 of 7 allogeneic LIP and 5 of 5 allogeneic
HIP animals.
Cytokine, IDO, and Adhesion Molecule Expression
in Kidneys after BMT
Table 3 lists the renal expression at the mRNA level of all
analyzed cytokines for the different treatment groups. IDO,
tumor necrosis factor a (TNF-a), interferon g (IFN-g),
interleukin-1a (IL-1a), IL-2, IL-6, and IL-10 were all
Figure 1. Serum and urine markers of renal function in acute GvHD. (A) Serum levels of urea. Serum urea levels do not significantly differ
among untreated controls, allogeneic, or syngeneic animals. One-way analysis of variance (ANOVA): P ¼ 0.17 for ctrl versus alloTx(LIP)
versus synTx(LIP); one-way ANOVA: P¼ 0.64 for ctrl versus alloTx(HIP) versus synTx (HIP).(B) Serum levels of creatinine. After allogeneic
transplantation, creatinine levels were significantly decreased in both protocol groups. Creatinine levels were unaffected by syngeneic
transplantation. One-way ANOVA (P ¼ 0.015): *P < 0.05 versus ctrl and synTx(LIP), one-way ANOVA (P ¼ 0.002): #P < 0.01 versus ctrl,
P < 0.05 versus synTx(HIP).(C) Urinary albumin/creatinine ratio as a marker of albuminuria in week 1 and week þ3. Only allogeneic
animals showed a significant increase in albuminuria after transplantation. HIP allogeneic animals had even significantly higher levels than LIP
allogeneic animals. Within the LIP group, allogeneic animals had the significantly highest albuminuria levels and the same finding applied to the
HIP group. t test: *P ¼ 0.02 versus alloTx(LIP) week 1. One-way ANOVA (P ¼ 0.002) in week þ3: *P < 0.01 versus ctrl, P < 0.05 versus
synTx(LIP). t test: #P < 0.001 versus alloTx(HIP) week 1. One-way ANOVA (P¼ 0.002) in weekþ3: #P < 0.01 versus ctrl and synTx(HIP).
One-way ANOVA (P ¼ 0.002) in week þ3: *P < 0.05 versus ctrl, #P < 0.01 versus ctrl, P < 0.05 versus alloTx(LIP).(D) Urinary levels of
N-acetyl-beta-D-glucosaminidase (NAG) in week1 and weekþ3. After allogeneic transplantation, urine NAG levels significantly increased,
but control and syngeneic animals did not show any change in NAG levels. HIP allogeneic animals tend to have higher NAG levels than LIP
allogeneic animals. Inside the LIP group, allogeneic animals have higher NAG levels than controls and only slightly higher NAG levels than
syngeneic animals. In the HIP group, allogeneic animals had significantly higher NAG levels than control and syngeneic animals. t test:
*P ¼ 0.048 versus alloTx(LIP) week 1. One-way ANOVA (P ¼ 0.011) in week þ3: *P < 0.05 versus ctrl, P ¼ 0.06 versus synTx(LIP). t test
#P < 0.001 versus alloTx(HIP) week1. One-way ANOVA (P < 0.001) in weekþ3: #P < 0.001 versus ctrl, P < 0.05 versus synTx(HIP). One-
way ANOVA (P ¼ 0.001) in week þ3: *P < 0.05 versus ctrl, P ¼ 0.13 versus alloTx(LIP), #P ¼ 0.001 versus ctrl. alloTx, allogeneically
transplanted animals; ANOVA, analysis of variance; ctrl, control group; GvHD, graft versus host disease; HIP; high-intensity protocol; LIP,
low-intensity protocol; NAG, N-acetyl-beta-D-glucosaminidase; synTx, syngeneically transplanted animals.
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upregulated at the mRNA level after allogeneic transplan-
tation compared to untreated and syngeneic transplanted
animals. Expression of TNF-a, IFN-g, IL-6, and IL-10 was
significantly higher in the HIP group than in the LIP group
after allogeneic BMT, reflecting the clinical severity of
acute GvHD in both groups. Interleukin-1 b (IL-1b) and
IL-11 were the only cytokines with a similar expression
level in all treatment groups. The expression of IL-4 was
highest in untreated control animals and significantly lower
after syngeneic and allogeneic BMT. A comparison of IL-4
expression between transplanted animals only showed
higher levels after allogeneic but not after syngeneic BMT.
However, the difference was only statistically significant
for LIP animals, whereas only a trend was detectable in HIP
animals (P ¼ 0.11 for alloTx(HIP) vs. synTx(HIP)). The
expression of the 2 adhesion molecules ICAM-1 and
VCAM 1 was significantly elevated after allogeneic BMT.
VCAM-1 also showed higher levels for syngeneic animals
than for controls.
Discussion
Prophylaxis and treatment of acute GvHD after allogeneic
BMT remain the main cornerstone in modern hematology
and oncology. Although different organ systems are known
to be affected by this life-threatening complication,2 renal
failure after BMT is attributed to several factors other than
GvHD as stated by Hingorani.7 A recent experimental study
by Higo et al. has indicated that kidneys may also be a
direct target of T cells in allogeneic BMT rats.16 In our
study, we used a fully mismatched mouse model of acute
GvHD to further address this topic. Mice were transplanted
according to 2 different intensity protocols with varying
irradiation doses and numbers of transplanted splenocytes
and bone marrow cells. As published previously, this type
of transplantation caused acute GvHD in allogeneic ani-
mals that was clinically more severe in the HIP group than
in the LIP group as indicated by the GvHD score and ani-
mal body weight. Syngeneic animals and untreated controls
did not develop GvHD.18
In our model, we first aimed to assess alterations in renal
function by different serum and urinary parameters. Serum
urea levels did not differ among the different groups (Fig.
1A). Elevated serum urea levels as an indicator of renal
injury and catabolic metabolism may have been expected,
but serum urea is also affected by fluid homeostasis and liver
function, which may explain our results. Serum creatinine
levels (Fig. 1B) that are typically elevated in renal failure
were even decreased in acute GvHD. Since creatinine is
mainly influenced by body muscle content, we suggest that
the observed decrease was caused by the loss of muscle mass
due to catabolic metabolism in the context of acute GvHD.
This hypothesis is also supported by the significant decrease
in body weight after allogeneic BMT. Because these classic
serum parameters of renal function did not seem to be prac-
tical for measuring renal injury in our animal model of
GvHD, we also assessed proteinuria, albuminuria, and urin-
ary NAG levels. We did not find any difference in protei-
nuria but a significant increase in albuminuria (Fig. 1C)
between week 1 and week þ3 in allogeneic animals. The
amount of albuminuria even correlated with the clinical
severity of GvHD between the LIP and the HIP groups,
indicating glomerular damage after allogeneic BMT. The
same results were yielded for urinary NAG (Fig. 1D) as a
marker of tubular injury. Since renal injury in GvHD may be
induced either by direct T-cell-mediated damage or indir-
ectly by the severe inflammatory state in systemic GvHD,7,20
albuminuria, and elevated NAG levels alone are not suffi-
cient to diagnose renal GvHD.
Therefore, we conducted histological examinations of the
kidneys that showed infiltration of mononuclear cells, caus-
ing endarteritis (Fig. 3A), interstitial nephritis (Fig. 3A and
B, tubulitis (Fig. 3A to C), and glomerulitis (Fig. 3D and F).
Figure 2. Histological alterations of kidneys in acute GvHD HE
(A,B), and PAS (C,D) stainings of kidneys after allogeneic BMT.
Mononuclear cell infiltrate was present in the renal interstitium
(arrows in A-D). Some cells had also infiltrated the tubules (arrow-
heads in D). In syngeneic animals (E and F), no pathological infiltra-
tion of mononuclear cells was detected (“g” indicates glomeruli, “t”
indicates tubules in E and F). (A-F magnification 40). BMT, bone
marrow transplantation; GvHD, graft versus host disease; HE,
hematoxylin/eosin; PAS, periodic-acid Schiff.
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Concomitantly to cell infiltrations, we could prove apoptosis
of tubular and glomerular cells (Fig. 3G and H) that was in
line with the above-mentioned level of albuminuria as a
marker of glomerular and elevated urinary NAG levels indi-
cating tubular injury. The cellular infiltrate consisted of
CD3þ T cells, CD4þ T cells, CD8þ T cells, FoxP3þ T
cells, and MAC2þ macrophages (Fig. 4). After allogeneic
BMT, the number of CD3þ T cells, CD4þ T cells, FoxP3þ
T cells, and MAC2þ macrophages was significantly
increased compared to that of syngeneic and control animals.
These findings reflect the pathophysiology of GvHD, in
which donor T cells get activated by antigen-presenting cells
(APCs) and proliferate, differentiate, and finally attack host
tissues.2,21 Both CD4þ and CD8þ cytotoxic T cells are
important effectors against major histocompatibility com-
plexes (MHCs) II and I22 and fundamental for the
development of acute GvHD. Thereby, the alloantigen com-
position of the host tissue is the main determinant for which
the T-cell subpopulation gets activated.21 Actually, it is not
clear why in our fully MHC-mismatched mouse model only
CD4þ and not CD8þ T cells were significantly increased.
This needs to be further investigated, since in the rat model
of Higo et al.16 CD8þ T cells also infiltrated the kidneys in
acute GvHD. FoxP3þ T cells have a regulatory effect on the
activation and proliferation of T cells that are known to be
able to preserve graft-versus-tumor activity and reduce
GvHD after BMT.23-25 A study on GvHD skin biopsies has
described an association of the increase in FoxP3þ T cells
with lower disease severity.26 Our data on kidneys are in line
with these results, since FoxP3þ T cells were elevated in
GvHD and even more in LIP animals with less severe
disease than in the HIP group. However, the role of
Figure 3. Immunhistological characterization of renal cell infiltrates and apoptosis in acute GvHD. Immunohistological staining for CD3
(A-D), MAC2 (E, F), and TUNEL(G, H) in kidneys after allogeneic BMT. CD3þ T cells were present around the vessels (endarteriitis,
arrowheads in A), migrated into the interstitium (interstitial nephritis, arrows in A and B) and infiltrated tubules (tubulitis, thin arrows in A
and C) and glomeruli (glomerulitis, arrows in D). MAC2þ macrophages were found in the interstitium (arrows in E) and infiltrate both
tubules (arrowheads in E and F) and glomeruli (arrows in F). This infiltration was accompanied by apoptosis of tubular (arrowheads in G and
H) and glomerular (arrows in G and H) cells. In contrast, after syngeneic BMT, no pathological infiltration of CD3þ T cells (I) and MAC2þ
macrophages (J) as well as apoptosis was observed (K). (A magnification 20, B-K magnification 40). BMT, bone marrow transplantation;
GvHD, graft versus host disease; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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Figure 4. Quantification of infiltrating cell subpopulations and apoptotic cells in kidneys in acute GvHD. Immunohistological quantification
of CD3þ T cells, CD4þ T cells, CD8þ T cells, FoxP3þ T cells, MAC2þmacrophages, and TUNELþ apoptotic cells in kidneys. Four weeks
after allogeneic BMT, CD3þ T cells and MAC2þ macrophages infiltrated the kidneys. T cells consist of CD4þ, CD8þ, and FoxP3þ cells.
The numbers of CD3þ (one-way ANOVA (P < 0.001): *P < 0.001 versus ctrl and synTx(LIP), #P < 0.001 versus ctrl and synTx(HIP)), CD4þ
(one-way ANOVA (P < 0.005): *P < 0.05 versus ctrl and synTx(LIP); one-way ANOVA (P¼ 0.004): #P < 0.05 versus ctrl and synTx(HIP)) and
FoxP3þ T cells (one-way ANOVA (P < 0.001): *P < 0.001 versus ctrl and synTx(LIP), #P < 0.001 versus ctrl and synTx(HIP)) as well as
MAC2þmacrophages (one-way ANOVA (P < 0.001): *P < 0.001 versus ctrl and synTx(LIP), #P < 0.001 versus ctrl and synTx(HIP)) per 40
magnification field were significantly higher in allogeneic mice than in untreated controls and syngeneic animals. FoxP3þ T cells showed a
significant difference between allogeneic animals with more cells in the LIP than in the HIP group (one-way ANOVA (P < 0.001): #P < 0.001
vs. ctrl and allo(LIP)). All other infiltrating cell subpopulations did not show any difference between the 2 allogeneic groups. CD8þ T cells did
not differ among all groups. Cell infiltration is accompanied by a significant increase in TUNELþ apoptotic cells (one-way ANOVA
(P < 0.001): *P < 0.001 versus ctrl, P < 0.01 versus synTx(LIP); one-way ANOVA (P ¼ 0.002): #P < 0.01 versus ctrl, P < 0.05 versus
synTx(HIP)). ANOVA, analysis of variance; alloTx, allogeneically transplanted animals; BMT, bone marrow transplantation; ctrl, control
group; GvHD, graft versus host disease; LIP, low-intensity protocol; HIP, high-intensity protocol; TUNEL, terminal deoxynucleotidyl
transferase dUTP nick end labeling; synTx, syngeneically transplanted animals.
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T-regulatory cells (Tregs) and their interplay with IDO,
which suppresses the activation of conventional T cells and
promotes the function of Tregs,27 for the severity of renal
GvHD needs to be further clarified. In summary, these find-
ings are suggestive of cell-mediated renal injury as could be
expected in GvHD.
In the pathophysiology of acute GvHD, not only cellular
factors such as T cells and macrophages are fundamental but
different cytokines also trigger and coordinate the attack of T
cells against the host tissue.2,21,28 To the best of our knowl-
edge, this is the first study to extensively analyze renal cyto-
kine expression in the context of GvHD including different
proinflammatory type 1 T helper (Th1)- and anti-
inflammatory Th2-cytokines.28,29 TNF-a, IFN-g, IL-1a,
IL-2, IL-6, and IL-10 were upregulated (Table 3). Higher
expression levels of TNF-a, IFN-g, IL-6, and IL-10 in allo-
geneic HIP animals were associated with more severe GvHD
compared to allogeneic LIP animals. The increase in proin-
flammatory cytokines, such as TNF-a, IL-1, and IL-6 termed
“danger signals,” was well in line with the actual understand-
ing of GvHD.29,30 These cytokines are produced during the
first step of GvHD as a consequence of damage to the host
tissue. In a second step, the cytokines generate a highly
inflammatory environment and promote the activation of T
cells by APCs. T cells proliferate, differentiate, and produce
large amounts of Th1-cytokines such as IFN-g and IL-2.
IFN-g has many different functions in GvHD and may
augment or reduce the clinical course of the disease.2,21 This
function also applies to IL-2, which may enhance the sever-
ity and mortality of GvHD30 and is also important for the
expansion of Tregs in chronic GvHD.31,32 In contrast, sim-
ilar to Th2-cytokines, IL-10 is generally considered anti-
inflammatory.33 After allogeneic BMT, the effect of IL-10
appears to be dose-dependent. In low doses, IL-10 seems to
be protective, but high doses are detrimental to the course of
GvHD.34-37 This fact matches our results, because HIP ani-
mals with more severe disease showed even higher renal
expression levels of IL-10 than the LIP group. IL-11 is also
known to have anti-inflammatory effects.38,39 Administra-
tion of IL-11 after allogeneic BMT protected against acute
GvHD and maintained the graft-versus-leukemia effect in a
mouse model.40,41 Yet, a study on humans had to be termi-
nated because of increased mortality after IL-11 applica-
tion.42 Our study could show similar expression levels in
all groups and no significant differences between allogeneic
and syngeneic animals. IL-4 also belongs to Th2-cytokines.
Elevated IL-4 levels have been described in acute
GvHD,43,44 and the beneficial effect of natural killer cells
on GvHD seems to be IL-4 dependent.45-48 We found renal
IL-4 expression to be significantly elevated in allogeneic LIP
animals compared to syngeneic animals. Allogeneic HIP
animals only showed a trend toward higher expression. Inter-
estingly, the highest expression levels could be detected in
untreated control animals, which would suggest that IL-4
Table 3. Relative Expression of IDO, Cytokines, and Adhesion Molecules in Kidneys.
Gene Ctrl AlloTx(LIP) SynTx(LIP) AlloTx(HIP) SynTx(HIP)
IDO 1.24 + 0.03 1.68 + 0.16* 1.04 + 0.16 1.96 + 0.20# 0.97 + 0.08
TNF-a 0.43 + 0.04 0.81 + 0.08* 0.41 + 0.02 1.35 + 0.20# 0.53 + 0.09
IFN-g 0.15 + .02 1.13 + 0.17* 0.11 + 0.03 2.05 + 0.29# 0.11 + 0.01
IL-1a 0.32 + 0.04 1.91 + 0.51* 0.44 + 0.04 2.43 + 0.52# 0.53 + 0.11
IL-1b 1.07 + 0.04 1.15 + 0.13 1.23 + 0.07 1.08 + 0.21 1.33 + 0.10
IL-2 0.46 + 0.05 2.91 + 0.43* 0.30 + 0.01 2.58 + 0.44# 0.31 + 0.06
IL-4 11.25 + 1.43y 5.19 + 1.41* 1.27 + 0.49 3.34 + 0.75 0.75 + 0.35
IL-6 0.33 + 0.05 1.13 + 0.12* 0.48 + 0.08 1.69 + 0.23# 0.82 + 0.03
IL-10 0.06 + 0.01 1.21 + 0.32* 0.04 + 0.02 2.27 + 0.45# 0.07 + 0.04
IL-11 0.73 + 0.02 1.04 + 0.08* 0.85 + 0.09 1.12 + 0.21 0.89 + 0.02
ICAM-1 0.68 + 0.06 1.05 + 0.10* 0.57 + 0.05 1.20 + 0.14# 0.74 + 0.01
VCAM-1 0.31 + 0.02 0.98 + 0.08* 0.57 + 0.11y 1.10 + 0.16# 0.63 + 0.04p
Abbreviations: ANOVA, analysis of variance; AlloTx, number of allogeneically transplanted and surviving animals after 4 weeks; IDO, indoleamine-2,3
dioxygenase; HIP, high-intensity protocol; IFN-g, interferong; IL, interleukin, ICAM-1, intercellular adhesion molecule 1; LIP, low-intensity protocol; SynTx,
number of syngeneically transplanted and surviving animals after 4 weeks; TNF-a, tumor necrosis factor a; VCAM-1: vascular cell adhesion molecule 1.
IDO: one-way ANOVA (P ¼ 0.021): *P < 0.05 versus synTx(LIP); one-way ANOVA (P ¼ 0.002): #< 0.01 versus synTx(HIP), P < 0.05 versus ctrl. TNFa:
one-way ANOVA (P ¼ 0.001): *P < 0.01 versus ctrl and synTx(LIP); one-way ANOVA (P < 0.001): #P < 0.01 versus ctrl and synTx(HIP); one-way ANOVA
(P < 0.001): *P < 0.05 versus alloTx(LIP). IFN-g: One-way ANOVA (P < 0.001): *P < 0.001 versus ctrl and synTx(LIP); one-way ANOVA (P < 0.001): #P < 0.001
versus ctrl and synTx(HIP); one-way ANOVA (P < 0.001): #P < 0.01 versus alloTx(LIP). IL-1a: one-way ANOVA (P ¼ 0.004): *P < 0.01 versus ctrl and
synTx(LIP); one-way ANOVA (P ¼ 0.003): #P < 0.01 versus ctrl, P < 0.05 versus synTx(HIP). IL-2: one-way ANOVA (P < 0.001): *P < 0.001 versus ctrl
and synTx(LIP); one-way ANOVA (P < 0.001): #P < 0.001 versus ctrl and synTx(HIP). IL-4: one-way ANOVA (P < 0.001): *P < 0.05 versus ctrl and synTx(LIP),
yP < 0.001 versus synTx(LIP); one-way ANOVA (P < 0.001): yP < 0.001 versus alloTx(HIP) and synTx(HIP). IL-6: one-way ANOVA (P < 0.001): *P < 0.001
versus ctrl and synTx(LIP); one-way ANOVA (P < 0.001): #P < 0.001 versus ctrl, P < 0.05 versus synTx(HIP); one-way ANOVA (P < 0.001): #P < 0.05 versus
alloTx(LIP). IL-10: one-way ANOVA (P ¼ 0.003): *P < 0.01 versus ctrl and synTx(LIP); one-way ANOVA (P < 0.001): #P < 0.001 versus ctrl and synTx(HIP);
one-way ANOVA (P¼ 0.001): #P < 0.05 versus alloTx(LIP). IL-11: one-way ANOVA (P¼ 0.023): *P < 0.05 versus ctrl. ICAM-1: one-way ANOVA (P¼ 0.002):
*P < 0.05 versus ctrl, P < 0.01 versus synTx(LIP); one-way ANOVA (P¼ 0.004): #P < 0.01 versus ctrl, P < 0.05 versus synTx(HIP). VCAM-1: one-way ANOVA
(P < 0.001): *P < 0.001 versus ctrl, P < 0.01 versus synTx(LIP), yP < 0.05 versus ctrl; one-way ANOVA (P < 0.001): #P < 0.001 versus ctrl, P < 0.05 versus
synTx(HIP), p P < 0.05 versus ctrl.
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expression could be decreased by irradiation. This finding
would be of interest, since irradiation normally favors the
development of regulatory natural killer cells accompanied
by elevated IL-4 levels,49 and in our recent study, IL-4
expression was not changed in mesenteric arteries of the
same animals.18 Whether this unexpected finding may be
specific for kidneys and whether it represents an effect of
antecedent radiation or other mechanisms need further
clarification.
Furthermore, we also quantified the expression of IDO.
IDO is known to be induced in inflammation and plays an
important role in immunomodulation and tumorigenesis.50,51
IDO is activated by IFN-g,52,53 lipopolysaccharides,54 TNF-
a,55 IL-6, and IL-1b.50 Its immunosuppressive effect results
from inhibited T-cell proliferation and the ability to activate
mature Tregs and to convert naive T cells to Tregs.50 IDO
activation is suggested to ameliorate GvHD severity and
mortality.56-58 High expression of IDO in intestinal mucosal
mononuclear cells and low expression in endothelial cells
were associated with favorable outcome in intestinal
GvHD.59 In our study, we could find higher IDO expression
levels after allogeneic BMT in both HIP and LIP animals.
Adhesion molecules play an important role in effector
cell migration and in trafficking into target organs in
GvHD.60 They are upregulated in the inflammatory milieu
mainly mediated by IL-1, TNF-a, and IFN-g.2,61 Our
results were in line with these findings because of the
increased expression of ICAM-1 and VCAM-1 after allo-
geneic BMT. Additionally, VCAM-1 showed significantly
higher expression in syngeneic than in control animals,
suggesting that VCAM-1 expression is also upregulated
by irradiation itself. Upregulation of different adhesion
molecules has been described for radiation-induced normal
tissue injury62 and especially for VCAM-1 in the case of
radiation-induced lung inflammation.63
Regarding our renal cytokine, IDO, and adhesion mole-
cule expression analysis in acute GvHD, there are some
limitations to admit. First, data in the literature often conflict
with regard to the expression of different cytokines in acute
GvHD. Often, levels of circulating cytokines are examined.
However, we present renal tissue expression in the current
study, and the 2 are not necessarily comparable. Second,
since we determined mRNA expression in whole kidney
samples, we cannot determine which cell populations, spe-
cifically infiltrating T cells or cells of renal parenchyma, are
the major sources of cytokine production. Third, we only
present data on mRNA expression and therefore know noth-
ing about the protein expression. Finally, it has to be stated
that the relative differences are often only small. Taking
these limitations into account, our expression data are diffi-
cult to interpret and further studies regarding the source of
cytokine production and determination of circulating and
protein levels are needed.
In summary, our current study affirms some of the results
from Higo et al.16 in our mouse model with different GvHD
severities and also adds some interesting new findings,
which may help to further understand renal GvHD. Our his-
tological investigations verified considerable renal infiltra-
tion by T cells and macrophages, causing endarteritis,
interstitial nephritis, tubulitis, and glomerulitis. Addition-
ally, with the TUNEL staining, we succeeded in correlating
the observed cell infiltrates with tissue damage and apoptosis
of tubular and glomerular cells. We confirmed elevated urin-
ary NAG levels as marker of tubular damage and are now the
first to describe albuminuria due to glomerular injury in
renal GvHD. Furthermore, we extended data regarding the
renal cytokine milieu with an extensive expression analysis
of cytokines and adhesion molecules, which resembled find-
ings from other tissues in GvHD. Of importance, with the
quantification of FoxP3þ T cells and the IDO expression,
we identified 2 new potential regulators of GvHD. However,
their exact role in the pathogenesis and severity of renal
GvHD warrants further study.
In conclusion, our current study further supports the
hypothesis of the existence of a renal form of GvHD char-
acterized by cell-mediated renal injury. Albuminuria and the
elevation of urinary NAG may be early markers for renal
impairment in acute GvHD. The exact pathophysiological
mechanisms, in particular the exact targets of T-cell attack
in the kidneys, the role of regulatory T cells, and the trypto-
phan metabolism need to be further elucidated to develop
potential prophylactic and therapeutic interventions.
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